81.89
-1.09 (-1.31%)
| Previous Close | 82.98 |
| Open | 83.65 |
| Volume | 682,477 |
| Avg. Volume (3M) | 1,074,585 |
| Market Cap | 14,203,620,352 |
| Price / Earnings (TTM) | 9.40 |
| Price / Earnings (Forward) | 13.50 |
| Price / Sales | 1.73 |
| Price / Book | 2.89 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | 4.56% |
| Operating Margin (TTM) | 7.73% |
| Diluted EPS (TTM) | 2.17 |
| Quarterly Revenue Growth (YOY) | 2.70% |
| Quarterly Earnings Growth (YOY) | -42.20% |
| Total Debt/Equity (MRQ) | 242.58% |
| Current Ratio (MRQ) | 1.19 |
| Operating Cash Flow (TTM) | 772.00 M |
| Levered Free Cash Flow (TTM) | 1.05 B |
| Return on Assets (TTM) | 3.72% |
| Return on Equity (TTM) | 10.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Mixed | |
| Stock | Solventum Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.5 |
| Average | 0.88 |
|
Solventum Corp is a healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer and patient needs. The company has four operating segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company generates the majority of its revenue from the MedSurg segment, which provides wound care and surgical solutions that are intended to accelerate healing, prevent complications, and lower the total cost of care globally. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Core |
| % Held by Insiders | 20.00% |
| % Held by Institutions | 67.75% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Independent Franchise Partners Llp | 30 Sep 2025 | 12,899,240 |
| Trian Fund Management, L.P. | 30 Sep 2025 | 8,462,819 |
| Madison Avenue Partners, Lp | 30 Sep 2025 | 1,988,376 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 100.00 (BTIG, 22.12%) | Buy |
| Median | 98.00 (19.67%) | |
| Low | 79.00 (UBS, -3.53%) | Hold |
| Average | 92.33 (12.75%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 76.30 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 02 Dec 2025 | 100.00 (22.12%) | Buy | 85.59 |
| UBS | 10 Nov 2025 | 79.00 (-3.53%) | Hold | 71.79 |
| 01 Oct 2025 | 77.00 (-5.97%) | Hold | 73.04 | |
| Piper Sandler | 07 Nov 2025 | 98.00 (19.67%) | Buy | 71.52 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 25 Nov 2025 | Announcement | Solventum to Participate in the 2025 Piper Sandler Healthcare Conference |
| 20 Nov 2025 | Announcement | Solventum Announces $1 Billion Share Repurchase Program |
| 20 Nov 2025 | Announcement | Solventum Announces Agreement to Acquire Acera Surgical |
| 06 Nov 2025 | Announcement | Solventum Reports Third Quarter 2025 Financial Results |
| 03 Nov 2025 | Announcement | Solventum to Participate in the 2025 Stifel Healthcare Conference |
| 21 Oct 2025 | Announcement | Solventum Appoints Heather Knight as Chief Commercial Officer |
| 16 Oct 2025 | Announcement | Solventum to Report Third Quarter Fiscal 2025 Earnings on November 6, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |